null When RSV weighs heavily on the Canadian health-care system
The adoption of preventive measures could alleviate this burden, shows a study carried out by researchers at the Montreal Children's Hospital and BC Children's Hospital Research Institute
Montreal, October 4, 2023 - Every winter, Canadian pediatric hospitals experience a wave of admissions linked to respiratory syncytial virus (RSV), one of the leading causes of hospitalization among children. These hospitalizations represent a major burden for the health-care system, and the adoption of preventive measures could certainly alleviate this burden, shows a study carried out by researchers at the Montreal Children's Hospital and BC Children's Hospital Research Institute.
RSV causes respiratory tract infections such as bronchiolitis and pneumonia. The research, published today in JAMA Network Open, identifies RSV-related hospitalizations between 2017 and 2022 in 13 Canadian pediatric tertiary care hospitals participating in the Immunization Monitoring Program ACTive (IMPACT) of the Canadian Paediatric Society. These represent over 90 per cent of pediatric tertiary care beds in the country. The study also shows the epidemic curve followed by the virus each year, including changes induced by the COVID-19 pandemic.
Nearly half (49.8 per cent) of the 11,014 RSV-related hospitalizations recorded during this period were in patients under six months of age. Almost a quarter of all hospitalizations (23.6 per cent) resulted in admission to intensive care and of these, 60.8 per cent were in children under six months of age.
"Every year, thousands of children become seriously ill with RSV in Canada. Our results suggest that preventive strategies for infants under six months of age have the potential to substantially decrease the RSV burden in Canadian children," notes Jesse Papenburg, MD, co-senior author of the study, pediatric infectious diseases specialist at the Montreal Children's Hospital and scientist in the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre.
These measures include the potential administration of a long-acting monoclonal antibody to infants (approved by Health Canada in April 2023), protecting them during their first RSV season.
Vaccination of pregnant women against RSV (currently under review by Health Canada) may also be considered. This would enable expectant mothers to develop antibodies they could pass on to their babies, who would be protected in the first months of life.
The importance of monitoring
The study also shows that, after a near absence during the 2020-2021 season, RSV-related hospitalizations increased in 2021-2022 (3,170 admissions) compared with the pre-pandemic period (average of 2,522 admissions per year).
Researchers noted an increase in RSV-related hospitalizations starting in summer 2021, particularly in Quebec, Saskatchewan and Alberta. Lower immunity due to the absence of infections in the previous year (likely because of measures to counter the pandemic), combined with children’s reengagement in social activities and relaxation of physical distancing, may explain this increase.
"This research is the first national study to describe RSV hospitalizations in Canadian pediatric hospitals with data from before and during the COVID-19 pandemic. Monitoring RSV seasonal variations is essential for pediatric health-care capacity planning," says Julie Bettinger, PhD, lead epidemiologist for IMPACT, scientist at BC Children's Hospital Research Institute, and professor of pediatric infectious diseases at the University of British Columbia.
For example, in Quebec, a summer 2021 surge in RSV and an abrupt halt in transmission in January 2022 prompted a start and end of the provincial palivizumab program approximately two months earlier than planned. Palivizumab is an antibody administered to more vulnerable babies because of their prematurity, chronic lung, or congenital heart disease.
"Our results highlight all the importance of both regional and national surveillance for RSV, especially considering that optimal use of monoclonal antibodies and vaccination of pregnant women depends in part on the timing of their administration in relation to virus activity," adds Dr. Papenburg, also assistant professor in the Department of Pediatrics at McGill University.
Case severity and percentage of cases by age, however, remained similar over the five years studied.
About the study
The study Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic was conducted by Malou Bourdeau, Nirma Khatri Vadlamudi, Nathalie Bastien, Joanne Embree, Scott A. Halperin, Taj Jadavji, Kescha Kazmi, Joanne M. Langley, Marc H. Lebel, Nicole Le Saux, Dorothy Moore, Shaun K. Morris, Jeffrey M. Pernica, Joan Robinson, Manish Sadarangani, Julie Bettinger, Jesse Papenburg and members of the Canadian Immunization Monitoring Program ACTive.
About the Montreal Children’s Hospital
Established in 1904, the Montreal Children's Hospital (MCH) is Quebec’s oldest children’s hospital and the pediatric hospital of the McGill University Health Centre (MUHC). A tertiary and quaternary care teaching and research facility, treating newborns, children and adolescents up to age 18, it serves 63 per cent of the geographic population of Quebec.
With its pediatric care and research facilities adjacent to the adult facility on the Glen site, the Children’s is in a unique position to offer services and research across the lifespan. The Centre for Innovative Medicine — the only clinical research centre in a hospital setting in North America — allows its researchers to conduct clinical trials on the Hospital site.
The Children's is a leader in providing a broad spectrum of highly specialized care to young patients and families from all across Quebec. The hospital is a provincially designated trauma centre and is recognized for its wealth of expertise in cardiology and cardiac surgery, emergency care, neurology and neurosurgery. thechildren.com
About the Research Institute of the MUHC
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and health-care research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) — an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 420 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Québec – Santé (FRQS). www.rimuhc.ca
About BC Children's Hospital Research Institute
BC Children's Hospital Research Institute conducts discovery, translational and clinical research to benefit the health of children and their families. We are supported by BC Children's Hospital Foundation, are part of BC Children’s Hospital and the Provincial Health Services Authority, and work in close partnership with the University of British Columbia. For more information, visit www.bcchr.ca
Communication agent, Montreal Children’s Hospital
Communications specialist, BC Children’s Hospital Research Institute